Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples